These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 35431535)

  • 1. COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants.
    Noor R; Shareen S; Billah M
    Bull Natl Res Cent; 2022; 46(1):96. PubMed ID: 35431535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2.
    Mahmoud S; Ganesan S; Al Kaabi N; Naik S; Elavalli S; Gopinath P; Ali AM; Bazzi L; Warren K; Zaher WA; Hosani FA
    J Clin Virol; 2022 Jun; 150-151():105161. PubMed ID: 35439702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covid-19 vaccines and variants of concern: A review.
    Hadj Hassine I
    Rev Med Virol; 2022 Jul; 32(4):e2313. PubMed ID: 34755408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness.
    Tulimilli SV; Dallavalasa S; Basavaraju CG; Kumar Rao V; Chikkahonnaiah P; Madhunapantula SV; Veeranna RP
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines.
    McLean G; Kamil J; Lee B; Moore P; Schulz TF; Muik A; Sahin U; Türeci Ö; Pather S
    mBio; 2022 Apr; 13(2):e0297921. PubMed ID: 35352979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants.
    Simões RSQ; Rodríguez-Lázaro D
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.
    Chansaenroj J; Suntronwong N; Kanokudom S; Assawakosri S; Yorsaeng R; Vichaiwattana P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Thongmee T; Auphimai C; Nilyanimit P; Wanlapakorn N; Sudhinaraset N; Poovorawan Y
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern.
    Yu X; Wei D; Xu W; Liu C; Guo W; Li X; Tan W; Liu L; Zhang X; Qu J; Yang Z; Chen E
    Nat Commun; 2022 Apr; 13(1):1788. PubMed ID: 35379815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
    Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
    Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
    Noor R
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.
    Rogliani P; Chetta A; Cazzola M; Calzetta L
    Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33807818
    [No Abstract]   [Full Text] [Related]  

  • 15. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy.
    Hamad M; AlKhamach DMH; Alsayadi LM; Sarhan SA; Saeed BQ; Sokovic M; Ben Hadda T; Soliman SSM
    Viral Immunol; 2023 Mar; 36(2):83-100. PubMed ID: 36695729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scope of SARS-CoV-2 variants, mutations, and vaccine technologies.
    Wambani J; Okoth P
    Egypt J Intern Med; 2022; 34(1):34. PubMed ID: 35368846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants.
    Zhang Y; Zheng X; Sheng W; Liang H; Zhao Y; Zhu X; Yang R; Zhang Y; Dong X; Li W; Pei F; Ding L; Chang Z; Deng L; Yuan G; Yang Z; Zhu D; Yang X; Wang H
    Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 36016098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world.
    Chavda VP; Yao Q; Vora LK; Apostolopoulos V; Patel CA; Bezbaruah R; Patel AB; Chen ZS
    Front Immunol; 2022; 13():961198. PubMed ID: 36263030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.